SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mankind Pharma - Quaterly Results

31 Jul 2025 Evaluate
The revenue for the June 2025 quarter is pegged at Rs. 25413.60 millions, about 5.34% up against Rs. 24126.20 millions recorded during the year-ago period.The Company's Net profit for the June 2025 quarter have declined marginally to Rs. 4127.60  millions as against Rs. 4764.20 millions reported during the corresponding quarter ended.The company reported a good operating profit of 7372.90 millions compared to 6720.80 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 25413.60 24126.20 5.34 25413.60 24126.20 5.34 94978.00 86292.50 10.07
Other Income 642.20 960.40 -33.13 642.20 960.40 -33.13 4932.10 2705.00 82.33
PBIDT 7372.90 6720.80 9.70 7372.90 6720.80 9.70 30557.60 25367.90 20.46
Interest 1467.00 66.30 2112.67 1467.00 66.30 2112.67 3717.60 163.30 2176.55
PBDT 5905.90 6654.50 -11.25 5905.90 6654.50 -11.25 26840.00 25204.60 6.49
Depreciation 969.30 913.30 6.13 969.30 913.30 6.13 3780.10 3352.60 12.75
PBT 4936.60 5741.20 -14.01 4936.60 5741.20 -14.01 23059.90 21852.00 5.53
TAX 809.00 977.00 -17.20 809.00 977.00 -17.20 4217.40 4125.70 2.22
Deferred Tax -112.40 -108.90 3.21 -112.40 -108.90 3.21 -481.90 12.40 -3986.29
PAT 4127.60 4764.20 -13.36 4127.60 4764.20 -13.36 18842.50 17726.30 6.30
Equity 412.73 400.59 3.03 412.73 400.59 3.03 412.60 400.60 3.00
PBIDTM(%) 29.01 27.86 4.15 29.01 27.86 4.15 32.17 29.40 9.44

Mankind Pharma Share Price

2123.20 18.50 (0.88%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×